Kayrak, MehmetBacaksiz, AhmetUlgen, Mehmet S.Vatankulu, Mehmet AkifZengin, KadriyeAyhan, Selim S.Basarali, Mustafa Kemal2020-03-262020-03-2620110910-83271615-2573https://dx.doi.org/10.1007/s00380-010-0036-xhttps://hdl.handle.net/20.500.12395/26720Coronary artery disease (CAD) is believed to be the single leading cause of death in both men and women in the world. Smoking is the most important risk factor for CAD. Smoking increases platelet aggregation and thrombus formation. CD40 ligand (CD40L) is a transmembrane glycoprotein derived from activated platelets. It participates in thrombus formation during the acute phase of acute myocardial infarction (MI). Elevation of CD40L identifies the patients who are at highest risk for cardiac events and who are likely to benefit from treatment with the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists. The purpose of this study was to evaluate levels of CD40L in smokers with acute MI. Fifty-seven patients with acute MI were enrolled in this study. Thirty-one smokers were compared with 26 non-smokers. Soluble CD40L level in the plasma was determined by a standard enzyme-linked immunosorbent assay. Circulating levels of CD40L were higher in the smokers' group. Smokers with acute MI may have increased risk for thrombotic complications during acute MI, and optimal antiaggregant therapy should be administered.en10.1007/s00380-010-0036-xinfo:eu-repo/semantics/openAccessAcute myocardial infarctionCD40 ligandSmokingArticle26213113720978895Q2WOS:000288259700002Q3